C Number:	MG96005
Lock Date:	Not Entered.
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both
PWG Approval Date	NONE

Experiment Number: 99930-98
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/18/2014
Time Report Requested: 23:41:54
First Dose M/F: NA / NA
Lab: NCTR

CD Rat MALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Disposition Summary				
Animals Initially In Study	**26**	**25**	**25**	**25**
Early Deaths				
Survivors				
Terminal Sacrifice	**26**	**25**	**25**	**25**
Animals Examined Microscopically	**26**	**25**	**25**	**25**
ALIMENTARY SYSTEM				
Liver	(26)	(0)	(0)	(25)
Hemorrhage	1 (4%)			
Hepatodiaphragmatic Nodule	1 (4%)			
Inflammation, Chronic	22 (85%)			22 (88%)
Necrosis	5 (19%)			2 (8%)
Vacuolization Cytoplasmic	8 (31%)			3 (12%)
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
Adrenal Cortex	(26)	(0)	(0)	(24)
Accessory Adrenal Cortical Nodule	2 (8%)			
Vacuolization Cytoplasmic				1 (4%)
Adrenal Medulla	(26)	(0)	(0)	(24)
Pituitary Gland	(26)	(0)	(0)	(25)
Mineralization	1 (4%)			
Pars Distalis, Cyst, Multiple				1 (4%)
Thyroid Gland	(26)	(0)	(0)	(25)
Inflammation, Chronic				1 (4%)
GENERAL BODY SYSTEM				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99930-98
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/18/2014
Time Report Requested: 23:41:54
First Dose M/F: NA / NA
Lab: NCTR

CD Rat MALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
GENITAL SYSTEM				
Coagulating Gland	(26)	(25)	(25)	(25)
Epididymis	(26)	(25)	(25)	(25)
Hypospermia	1 (4%)	1 (4%)		
Infiltration Cellular, Lymphocyte	2 (8%)	1 (4%)	1 (4%)	2 (8%)
Preputial Gland	(0)	(0)	(0)	(1)
Inflammation, Chronic				1 (100%)
Prostate	(3)	(8)	(5)	(3)
Prostate, Dorsal Lobe	(26)	(25)	(25)	(24)
Epithelium, Hyperplasia			1 (4%)	
Inflammation, Chronic	8 (31%)	4 (16%)	5 (20%)	9 (38%)
Inflammation, Suppurative	8 (31%)	7 (28%)	12 (48%)	13 (54%)
Prostate, Ventral Lobe	(26)	(25)	(25)	(24)
Inflammation, Chronic	20 (77%)	15 (60%)	18 (72%)	13 (54%)
Inflammation, Suppurative		5 (20%)	2 (8%)	3 (13%)
Rete Testes	(26)	(25)	(23)	(25)
Seminal Vesicle	(26)	(25)	(25)	(25)
Dilatation		2 (8%)		3 (12%)
Testes	(26)	(25)	(25)	(25)
Seminif Tub, Degeneration	1 (4%)	2 (8%)	1 (4%)	2 (8%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(26)	(0)	(0)	(25)
Spleen	(26)	(0)	(0)	(25)
Adventitia, Inflammation, Chronic	1 (4%)			
Hyperplasia, Stromal				2 (8%)
Pigmentation	6 (23%)			5 (20%)
Red Pulp, Fibrosis	1 (4%)			
Thymus	(26)	(0)	(0)	(25)
Hemorrhage	1 (4%)			1 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99930-98
Test Type: SPECIAL STUDY
Route: DOSED FEED
Species/Strain: Rat/CD

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
Test Compound: Endocrine disruptor (Genistein)
CAS Number: 446-72-0

Date Report Requested: 10/18/2014
Time Report Requested: 23:41:54
First Dose M/F: NA / NA
Lab: NCTR

CD Rat MALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
INTEGUMENTARY SYSTEM				
Mammary Gland	(26)	(24)	(25)	(25)
Alveolus, Hyperplasia	1 (4%)		3 (12%)	10 (40%)
Duct, Hyperplasia		1 (4%)	2 (8%)	8 (32%)
Skin	(26)	(0)	(0)	(25)
MUSCULOSKELETAL SYSTEM				
Bone, Femur	(26)	(0)	(0)	(25)
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
None				
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(26)	(25)	(25)	(25)
Capsule, Fat, Cyst		1 (4%)		1 (4%)
Casts Protein	1 (4%)			1 (4%)
Cortex, Cyst		2 (8%)		1 (4%)
Cortex, Cyst, Multiple				1 (4%)
Epithelium, Hyperplasia				1 (4%)
Epithelium, Pelvis, Hyperplasia		1 (4%)		
Infiltration Cellular, Lymphocyte			1 (4%)	
Inflammation, Chronic	16 (62%)	16 (64%)	19 (76%)	22 (88%)
Pelvis, Dilatation			1 (4%)	
Renal Tubule, Dilatation	5 (19%)	6 (24%)	2 (8%)	8 (32%)
Renal Tubule, Mineralization	1 (4%)	3 (12%)	8 (32%)	15 (60%)
Renal Tubule, Regeneration	6 (23%)	6 (24%)	8 (32%)	19 (76%)

a - Number of animals examined microscopically at site and number of animals with lesion

CD Rat MALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Renal Tubule, Vacuolization Cytoplasmic				1 (4%)

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

CD Rat FEMALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Disposition Summary				
Animals Initially In Study	**25**	**25**	**25**	**25**
Early Deaths				
Natural Death	**1**			
Survivors				
Terminal Sacrifice	**24**	**25**	**25**	**25**
Animals Examined Microscopically	**25**	**25**	**25**	**25**
ALIMENTARY SYSTEM				
Liver	(25)	(1)	(0)	(25)
Autolysis	1 (4%)			
Developmental Malformation				1 (4%)
Inflammation, Chronic Active, Focal	4 (16%)			5 (20%)
Necrosis, Focal				1 (4%)
Salivary Glands	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
Stomach, Forestomach	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
CARDIOVASCULAR SYSTEM				
Heart	(1)	(0)	(0)	(0)
Cardiomyopathy, Focal	1 (100%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(25)	(0)	(0)	(25)
Autolysis	1 (4%)			
Hyperplasia, Focal				1 (4%)
Adrenal Medulla	(25)	(0)	(0)	(25)
Autolysis	1 (4%)			
Pituitary Gland	(25)	(0)	(0)	(25)
Autolysis	1 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

CD Rat FEMALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Rathkes Cleft, Cyst	1 (4%)			2 (8%)
Thyroid Gland	(25)	(0)	(0)	(25)
Autolysis	1 (4%)			
Bilateral, Infiltration Cellular, Lymphocyte, Focal				1 (4%)
Bilateral, Ultimobranchial Cyst	1 (4%)			
Ultimobranchial Cyst				1 (4%)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Ovary	(25)	(25)	(25)	(25)
Autolysis	1 (4%)			
Cyst		1 (4%)		1 (4%)
Diestrus	8 (32%)	2 (8%)	4 (16%)	8 (32%)
Estrus	7 (28%)	8 (32%)	6 (24%)	5 (20%)
Metestrus	1 (4%)	6 (24%)	7 (28%)	5 (20%)
Proestrus	8 (32%)	9 (36%)	7 (28%)	7 (28%)
Oviduct	(25)	(25)	(25)	(25)
Uterus	(25)	(25)	(25)	(25)
Angiectasis, Focal		1 (4%)		
Autolysis	1 (4%)			
Decidual Reaction	22 (88%)	20 (80%)	21 (84%)	20 (80%)
Diestrus	8 (32%)	2 (8%)	4 (16%)	7 (28%)
Endometrium, Dilatation				1 (4%)
Endometrium, Inflammation, Diffuse		1 (4%)		
Estrus	6 (24%)	8 (32%)	7 (28%)	5 (20%)
Inflammation, Chronic Active, Focal		1 (4%)		
Metestrus	2 (8%)	5 (20%)	7 (28%)	5 (20%)
Proestrus	8 (32%)	9 (36%)	7 (28%)	8 (32%)
Vagina	(25)	(25)	(25)	(25)

a - Number of animals examined microscopically at site and number of animals with lesion

CD Rat FEMALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Autolysis	1 (4%)			
Diestrus	8 (32%)	1 (4%)	4 (16%)	7 (28%)
Estrus	9 (36%)	10 (40%)	7 (28%)	5 (20%)
Infiltration Cellular, Polymorphnuclr		1 (4%)		
Metestrus	2 (8%)	6 (24%)	7 (28%)	6 (24%)
Proestrus	5 (20%)	7 (28%)	7 (28%)	7 (28%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(25)	(0)	(0)	(25)
Lymph Node, Mandibular	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
Lymph Node, Mesenteric	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
Spleen	(25)	(0)	(0)	(25)
Autolysis	1 (4%)			
Thymus	(25)	(0)	(0)	(25)
INTEGUMENTARY SYSTEM				
Mammary Gland	(24)	(23)	(25)	(25)
Alveolus, Hyperplasia	8 (33%)	6 (26%)	14 (56%)	8 (32%)
Galactocele	1 (4%)		1 (4%)	
Lobules, Hyperplasia	1 (4%)	2 (9%)	2 (8%)	
Skin	(25)	(0)	(1)	(25)
Lip, Abscess			1 (100%)	
MUSCULOSKELETAL SYSTEM				
Bone, Femur	(25)	(0)	(0)	(25)
NERVOUS SYSTEM				
Brain, Brain Stem	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
Brain, Cerebellum	(1)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

CD Rat FEMALE	F1 0 PPM	F1 5 PPM	F1 100 PPM	F1 500 PPM
Autolysis	1 (100%)			
Brain, Cerebrum	(1)	(0)	(0)	(0)
Autolysis	1 (100%)			
RESPIRATORY SYSTEM				
Lung	(1)	(0)	(0)	(0)
Congestion, Diffuse	1 (100%)			
Nose	(1)	(0)	(0)	(0)
Congestion, Diffuse	1 (100%)			
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(25)	(25)	(24)	(25)
Autolysis	1 (4%)			
Bilateral, Nephropathy	2 (8%)			
Cyst	1 (4%)			
Cyst, Multiple		1 (4%)		1 (4%)
Infarct	1 (4%)			
Inflammation, Chronic Active			1 (4%)	
Mineralization	21 (84%)	23 (92%)	22 (92%)	24 (96%)
Nephropathy				2 (8%)
Pelvis, Dilatation		1 (4%)		1 (4%)

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion